title: The effects of Ins2(Akita) diabetes and chronic angiotensin II infusion on cystometric properties in mice.
abstract: OBJECTIVE
  Diabetes is associated with both dysfunction of the lower urinary tract (LUT) and overactivity of the renin-angiotensin system (RAS). Although it is well known that the RAS affects normal LUT function, very little is known about RAS effects on the diabetic LUT. Accordingly, we investigated the effects of chronic angiotensin II (AngII) treatment on the LUT in a model of type 1 diabetes.
  
  
  METHODS
  Ins2(Akita) diabetic mice (20 weeks old) and their age-matched background controls underwent conscious cystometric evaluation after 4 weeks of chronic AngII treatment (700 ng/kg/min by osmotic pump) or vehicle (saline).
  
  
  RESULTS
  Diabetic mice had compensated LUT function with bladder hypertrophy. Specifically, micturition volume, residual volume, and bladder capacity were all increased, while voiding efficiency and pressure generation were unchanged as bladder mass, contraction duration, and phasic urethral function were increased. AngII significantly increased voiding efficiency and peak voiding pressure and decreased phasic frequency irrespective of diabetic state and, in diabetic but not normoglycemic control mice, significantly decreased residual volume and increased contraction duration and nonphasic contraction duration.
  
  
  CONCLUSIONS
  The Ins2(Akita) diabetic mice had compensated LUT function at 20 weeks of age. Even under these conditions, AngII had beneficial effects on LUT function, resulting in increased voiding efficiency. Future studies should therefore be conducted to determine whether AngII can rescue the decompensated LUT function occurring in end-stage diabetic uropathy.
authors: Paul C
authors: PC
authors: Dolber
authors: Huixia
authors: H
authors: Jin
authors: Rashid
authors: R
authors: Nassar
authors: Thomas M
authors: TM
authors: Coffman
authors: Susan B
authors: SB
authors: Gurley
authors: Matthew O
authors: MO
authors: Fraser
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D008297:Male; D051379:Mice; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology*; D001745:Urinary Bladder Diseases / Q000503:physiopathology; D014554:Urination / Q000187:drug effects* / Q000502:physiology
chemical_list: D000804:Angiotensin II
references: Comp Biochem Physiol C. 1985;82(2):357-61
references: 2866909
references: Jpn J Pharmacol. 1989 Aug;50(4):369-76
references: 2779004
references: J Pharmacol Methods. 1991 Nov;26(3):161-71
references: 1753742
references: Acta Physiol Scand. 1992 Jul;145(3):253-9
references: 1519483
references: J Urol. 1993 Sep;150(3):1056-9
references: 8345584
references: Diabetes. 1997 May;46(5):887-94
references: 9133560
references: Br J Pharmacol. 1997 Jul;121(6):1081-6
references: 9249242
references: Circ Res. 1998 Dec 14-28;83(12):1182-91
references: 9851935
references: Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1728-35
references: 16439670
references: J Urol. 2006 Jul;176(1):380-6
references: 16753447
references: Drugs. 2006;66(9):1169-77
references: 16827595
references: Neurourol Urodyn. 2007;26(1):71-80
references: 17123298
references: Am J Physiol Cell Physiol. 2007 Jan;292(1):C82-97
references: 16870827
references: Clin Sci (Lond). 2007 Jun;112(7):375-84
references: 17324119
references: Endocr J. 2007 Apr;54(2):211-9
references: 17237611
references: Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R144-54
references: 18463192
references: J Hypertens Suppl. 2009 Jun;27(2):S3-7
references: 19491620
references: Eur Urol. 2009 Feb;55(2):482-9
references: 18378069
references: J Urol. 2009 Dec;182(6 Suppl):S18-26
references: 19846137
references: Am J Physiol Renal Physiol. 2010 Mar;298(3):F788-95
references: 20042456
references: Am J Physiol Renal Physiol. 2010 Mar;298(3):F771-8
references: 20042459
references: J Urol. 2011 Jul;186(1):334-40
references: 21600603
references: J Clin Invest. 2011 Jul;121(7):2845-54
references: 21701066
references: Hypertension. 2012 Feb;59(2):348-54
references: 22184325
references: J Urol. 2013 Apr;189(4):1580-7
references: 23103236
references: Am J Physiol. 1986 Dec;251(6 Pt 2):R1177-85
references: 3789199
references: Adv Exp Med Biol. 1999;462:183-91
references: 10599423
references: Pharmacol Rev. 2000 Mar;52(1):11-34
references: 10699153
references: BJU Int. 2000 Sep;86(4):494-501
references: 10971280
references: J Urol. 2004 Mar;171(3):1348-52
references: 14767346